Overview

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

Status:
Not yet recruiting
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
To find the highest tolerable dose of an mRNA vaccine that can be safely given to patients with cutaneous angiosarcoma
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Cancer Cures 4 Kids
Treatments:
Interferon alpha-2
Interferon-alpha
Interferons
Paclitaxel
Peginterferon alfa-2a